These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36122172)

  • 1. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.
    Connelly K; Kandane-Rathnayake R; Hoi A; Louthrenoo W; Hamijoyo L; Luo SF; Wu YJ; Cho J; Lateef A; Lau CS; Chen YH; Navarra S; Zamora L; Li Z; An Y; Sockalingam S; Hao Y; Zhang Z; Chan M; Katsumata Y; Harigai M; Oon S; Bae SC; O'Neill S; Gibson KA; Basnayake B; Kikuchi J; Takeuchi T; Ng KPL; Tugnet N; Kumar S; Goldblatt F; Law A; Tee M; Tee C; Tanaka Y; Ohkubo N; Tan JY; Karyekar CS; Nikpour M; Golder V; Morand EF
    Arthritis Rheumatol; 2023 Mar; 75(3):401-410. PubMed ID: 36122172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
    Touma Z; Gladman DD; Ibañez D; Taghavi-Zadeh S; Urowitz MB
    J Rheumatol; 2011 Nov; 38(11):2395-9. PubMed ID: 21885488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
    Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
    Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
    Morand EF; Isenberg DA; Wallace DJ; Kao AH; Vazquez-Mateo C; Chang P; Pudota K; Aranow C; Merrill JT
    Rheumatology (Oxford); 2020 Oct; 59(10):2930-2938. PubMed ID: 32107560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months.
    Touma Z; Urowitz MB; Taghavi-Zadeh S; Ibañez D; Gladman DD
    Rheumatology (Oxford); 2012 Oct; 51(10):1814-9. PubMed ID: 22718868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus.
    Leosuthamas P; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Int J Rheum Dis; 2023 Apr; 26(4):667-672. PubMed ID: 36802112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lupus Low Disease Activity State and Reduced Direct Health Care Costs in Patients With Systemic Lupus Erythematosus.
    Yeo AL; Koelmeyer R; Kandane-Rathnayake R; Golder V; Hoi A; Huq M; Hammond E; Nab H; Nikpour M; Morand EF
    Arthritis Care Res (Hoboken); 2020 Sep; 72(9):1289-1295. PubMed ID: 31282076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
    Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.
    Hao Y; Oon S; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Morand EF; Nikpour M; Zhang Z
    Clin Rheumatol; 2022 Feb; 41(2):357-366. PubMed ID: 34595670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K; Schmidt W; Leszczyński P
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE.
    Furie R; Wang L; Illei G; Drappa J
    Lupus; 2018 May; 27(6):955-962. PubMed ID: 29460699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.